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ABSTRACT: The cryopreservation of cells underpins many
areas of biotechnology, healthcare, and fundamental science
by enabling the banking and distribution of cells. Cryopro-
tectants are essential to prevent cold-induced damage. Here,
we demonstrate that extracellular localization of antifreeze
proteins can signiﬁcantly enhance post-thaw recovery of
mammalian cell monolayers cryopreserved using dimethyl
sulfoxide, whereas they show less beneﬁt in suspension
cryopreservation. A type III antifreeze protein (AFPIII) was
used as the macromolecular ice recrystallization inhibitor and
its intra/extracellular locations were controlled by using Pep-1,
a cell-penetrating peptide. Flow cytometry and confocal
microscopy conﬁrmed successful delivery of AFPIII. The presence of extracellular AFPIII dramatically increased post-thaw
recovery in a challenging 2-D cell monolayer system using just 0.8 mg·mL−1, from 25% to over 60%, whereas intracellularly
delivered AFPIII showed less beneﬁt. Interestingly, the antifreeze protein was less eﬀective when used in suspension
cryopreservation of the same cells, suggesting that the cryopreservation format is also crucial. These observations show that, in
the discovery of macromolecular cryoprotectants, intracellular delivery of ice recrystallization inhibitors may not be a signiﬁcant
requirement under “slow freezing” conditions, which will help guide the design of new biomaterials, in particular, for cell
storage.
■ INTRODUCTION
Cell-based therapies are emerging as next-generation treat-
ments for intractable and complex diseases (especially in
oncology) which remain unresponsive to traditional “molec-
ular” therapies.1 However, mammalian cell cryopreservation,
for the long-term storage of cells and tissues, remains an
essential part of the manufacturing process and has been
identiﬁed as a potential bottleneck in the future development
of complex cellular therapy products.2 Dimethyl sulfoxide
(DMSO), a cell permeable cryoprotectant, remains the most
widely used cryoprotective agent (CPA) for the cryopreserva-
tion of mammalian cells and tissues in cell suspension.3 During
typical “slow freezing” approaches, DMSO enters cells and
minimizes injury through reducing electrolyte concentration in
residual unfrozen solution within and surrounding cells at any
given temperature, thus reducing intracellular ice growth, cell
shrinkage and osmotic shock during freezing.4,5 However, cell
survival rates decrease due to DMSO cytotoxicity and
inhibition of internal signaling.6,7 Furthermore, prolonged
cryopreservation of stem cells approved for the treatment of
various blood and immunological diseases and for large-scale
banking and manufacturing can result in diﬀerentiation
induced by histone alterations and DNA methylation, creating
diﬃculties in the cryopreservation of material routinely used in
clinical applications.8−11
Cryopreservation of cells in monolayer format is currently
being investigated as a means to supply cells which can be
readily used and do not experience extensive “phenotypic drift”
due to time-consuming laboratory processes, such as
inoculation and propagation, from frozen vials. Successful
monolayer cryopreservation of cells would be revolutionary in
minimizing batch-to-batch variation and for the development
of 2- and 3-D cell models, tissue storage, viral diagnostics, and
organ-on-a-chip applications.12−15 However, the current stand-
ard (DMSO) approaches used in suspension freezing are not
translatable to monolayer freezing, with evidence suggesting
that cells within a 2- and 3-D network (monolayers and
spheroids/organoids) experience diﬀerent modes of cryoin-
jury.16,17 Thus, development of novel cryoprotectants tailored
toward the format of cryopreservation and to replace or reduce
DMSO content is pivotal for the future development of cell-
based therapies and diagnostics.
Naturally occurring CPAs, including trehalose,18 proline,17
sucrose,19 and antifreeze proteins (AFPs),20,21 as well as
synthetic cryoprotectants,22−24 have been studied in the
attempt to replace or improve DMSO cell suspension
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cryopreservation. In particular, AFPs (and their mimics) have
received attention due to their potent ice recrystallization
inhibition (IRI) properties and potential ability to stabilize
membranes or modify ice nucleation.25−28 Ice recrystallization
(growth) during thawing results in the formation of large ice
crystals, at the expense of small crystals, causing cellular
damage and is thus a major contributor to cell death. Although
IRI active compounds have provided some beneﬁts for
cryopreserving erythrocytes,29−33 nucleated cell lines,34,35 and
stem cells,36 complete removal of DMSO is rarely achieved.
Furthermore, the inﬂuence of IRI active compounds on cells
frozen in a monolayer format is poorly understood, as the
mechanism of cryoinjury is diﬀerent. Cell death during
monolayer freezing is postulated to be caused by the
propagation of intracellular ice between adjacent cells initiated
by multiple mechanisms including surface-catalyzed nuclea-
tions (i.e., extracellular ice interacting with cell membrane
forming a nucleation site for intracellular ice growth),37,38
cell−cell and cell−surface interaction with adjacent cells,39−41
or gap junctions within the membrane.16,42−44 Controlled slow
freezing of suspension cells with DMSO (typically 5−10 wt %)
removes the risk of intracellular ice formation as the CPA
enters the cells, causing more water to eﬄux, and reducing the
likelihood of intracellular ice formation.45−47 However, in the
extracellular media, ice formation and growth does occur,
hence the potential beneﬁts of ice recrystallization inhibitors.
Conversely, monolayer freezing of cells using DMSO typically
results in low post-thaw viability due to the intercellular
contacts and limited diﬀusion between cells suggesting that
monolayer freezing may beneﬁt from intracellular IRI active
macromolecules.17,48 Therefore, raising the question, “does the
diﬀerence in ice growth during slow-freezing of cells in
suspension and monolayer formats aﬀect the beneﬁts of intra-
versus extracellular localization of IRI active macromolecular
cryoprotectant?” Bailey et al.,48 Graham et al.,17 and
Matsumura et al.49 have previously shown that macromolecular
cryoprotectants can have dramatic eﬀects on cell monolayer
cryopreservation. However, determining the ideal cellular
location for macromolecular cryoprotectants would aid in the
understanding and development of emerging cryoprotectants,
especially since intracellular delivery of synthetic and natural
macromolecules can be challenging.50
Considering the above, the aim of this study was to evaluate
whether intra- or extracellular localization of ice recrystalliza-
tion inhibition active macromolecules is advantageous to the
cryopreservation of cells in suspension, monolayer, or both.
Using a type III AFP (AFPIII) and an eﬃcient cell-penetrating
peptide, Pep-1, we delivered AFPIII inside or outside of cells.
Extracellular AFPIII lead to a dramatic enhancement in the
cryopreservation of a 2-D cell monolayer system, resulting in a
3-fold increase in the total number of cells recovered compared
to 10 wt % DMSO alone. In contrast, intracellular AFPIII only
protected cells at a lower DMSO concentration, although with
high variability, supporting the hypothesis that extracellular ice
growth is a major cause of cell death. AFPIII failed to improve
cell recoveries in suspension freezing regardless of localization.
These results will help the rational design of more potent
macromolecular cryopreservatives.
■ EXPERIMENTAL SECTION
Materials. Pep-1, Dulbecco phosphate buﬀered saline (DPBS),
NucBlue Live Cell ReadyProbes Reagent, Alexa Fluor 488
C5Maleimide, ProLong Gold Antifade Alamar blue, Nalgene
cryogenic tubes, 175 cm2 Nunc cell culture ﬂasks, Fisherbrand Sterile
Cell Strainers, BD Sphero Rainbow Calibration Particles (8 Peaks
3.0−3.4 μm) and BD FACSFlow Sheath Fluid were purchased from
Fisher Scientiﬁc (Loughborough, UK). Ham’s F-12K (Kaighn’s)
Medium (F-12K) (Gibco, Paisley, UK) was supplemented with 10%
USA-origin fetal bovine serum (FBS) purchased from Sigma-Aldrich
(Dorset, UK), 100 units/mL penicillin, 100 μg/mL streptomycin, and
250 ng/mL amphotericin B (PSA) (HyClone, Cramlington, UK).
Physical and Analytical Methods. Ice Recrystallization
Inhibition Assay (IRI). IRI was assessed using a Linkam Biological
Cryostage BCS196 controlled with a T96-Linpad system controller
equipped with a LNP95-Liquid nitrogen cooling pump (Linkam
Scientiﬁc Instruments UK, Surrey, UK). Images were acquired using
an Olympus CX41 microscope UIS-2 20×/0.45/∞/0-2/FN22 lens
(Olympus Ltd., Southend on sea, UK) and a Canon EOS 500D SLR
digital camera. Image processing and mean grain size measurements
were completed using ImageJ 1.49v.
Confocal Microscopy. A Zeiss LSM 880 inverted microscope
equipped with 100×, 63×, 40×, and 20× oil immersion objective
lenses, three photomultiplier detectors (GaAsP, multialkali and
BiG.2) and multichannel spectral imaging with an ultrasensitive
GASP detector was used to acquire all confocal images. The UV and
VIS Laser Modules allowed selection of six lasers with wavelengths of
633, 594, 561, 543, 514, 488, 458, 405, and 355 nm. Zeiss ZEN (blue
edition) 2.3 lite was utilized for image collection and processing. All
other imaging was completed using an Olympus CX41 microscope
equipped with a UIS-2 20×/0.45/∞/0-2/FN22 lens (Olympus Ltd.,
Southend on sea, U.K.) and a Canon EOS 500D SLR digital camera
and processed using ImageJ 1.49v.
Flow Cytometry. Flow cytometry was performed on a BD Inﬂux
cell sorter (BD Biosciences) equipped with 355-, 488-, 561-, and 642
nm lasers and detecting up to 24 parameters (21 ﬂuorescence
channels, two forward scatter channels and one side scatter). BD
FACS Sortware software was used to operate the instrument. Sample
analysis required the use of the 488 nm excitation laser and 530/30
nm ﬁlter. A 100 μm nozzle was ﬁtted, operating at a pressure of 20 psi
(sheath) and 21.5 psi (sample). Stream and laser alignment was
performed using BD Sphero Rainbow Calibration Particles (8 Peaks,
3.0−3.4 μm), and all sample measurements consisted of a minimum
of 100 000 recorded events. Cell detachment was completed utilizing
Accutase solution (Fisher Scientiﬁc) and passed through Fisherbrand
Sterile Cell Strainers (Fisher Scientiﬁc) to ensure single cell analysis.
Voltage settings applied ensured that nonﬂuorescent control cells
appeared at low ﬂuorescence emission intensities. FlowJo X 10.0.7r2
(Tree Star, Ashland, USA) was used for all statistical analysis and
plotting of ﬂow cytometry data.
Statistical Analysis. Data was analyzed with a one-way analysis of
variance (ANOVA) on ranks followed by a comparison of
experimental groups with the appropriate control group (Tukey’s
post hoc test). R (R Foundation for Statistical Computing, Vienna,
Austria) was used for all statistical analysis.
AFPIII Cytotoxicity. A549 cells were plated in a 96-well plate
(Corning Incorporated, Corning, NY) at a density of 2 × 105 cells·
mL−1 with media supplemented with varying concentrations of
AFPIII (0−0.8 mg·mL−1) and incubated in a humidiﬁed atmosphere
of 95% air and 5% CO2 at 37 °C for 24 h. Alamar blue reagent (10%
v/v in cell media) was added to both AFPIII treated and untreated
(control) cells. Absorbance measurements were obtained at 570 and
600 nm using a BioTek Synergy HT microplate reader to monitor the
reduction of resazurin to resoruﬁn by viable cells. Cells were
incubated for 4 h at 37 °C and 5% CO2 with readings obtained every
30 min/1 h. Total cell viability was reported relative to control cells
grown solely in cell culture media alone.
Optimization of AFPIII Concentration for Vial Freezing.
A549 cells were obtained from an adherent culture by detaching with
0.25% trypsin and 1 mM EDTA in balanced salt solution, for 10 min,
in a humidiﬁed atmosphere of 5% CO2 and 95% air, at 37 °C. Viable
cells were counted using a hemocytometer (Sigma-Aldrich), following
treatment with 0.4% trypan blue solution (Sigma-Aldrich), and placed
in cryogenic vials at a density of 200k cell·mL−1 (400k cells per vial)
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in F12-K media supplemented with 10% FBS, varying concentrations
of AFPIII (0−0.8 mg·mL−1), and DMSO (0−10 wt %). Cryogenic
vials were placed in a CoolCell LX freezing container (BioCision,
LLC, Larkspur, CA), and frozen at 1 °C·min−1 to −80 °C. Vials were
subsequently stored in the vapor phase of a liquid nitrogen dewar
(−196 °C) for 24 h. Cells were rapidly thawed at 37 °C, transferred to
warm complete FK-12 media (9 mL), and centrifuged at 2g for 5 min.
The cell pellet was resuspended in complete media, transferred into a
24-well plates (Corning Incorporated, Corning, NY), and incubated
in a humidiﬁed atmosphere of 5% CO2 and 95% air at 37 °C for 24 h.
Finally, cell viability was assessed by counting the number of viable
cells (i.e., with intact membrane), as described above, and dividing by
the total number of cells initially frozen. Four biological repeats were
conducted.
Optimization of AFPIII Transfection Using Pep-1. A549 cells
were plated in a 24-well plate at a density of 800k cell·mL−1 (400k cell
per well), to achieve a conﬂuent monolayer, and left to attach for 24 h
in a humidiﬁed atmosphere of 5% CO2 and 95% air at 37 °C. Pep-1
(1 mg·mL−1), dissolved in ultrapure H2O, and AFPIII-Alexa Fluor
488 (0.25−2 mg·mL−1), dissolved in PBS, were mixed in a 1:1 ratio
and incubated at room temperature for 30 min. Cells were incubated
with the AFPIII-Alexa Fluor 488/Pep-1 mixtures (100 μL) for 30 min
in a humidiﬁed atmosphere and for a further 1 h after adding F12-K
media without an additional supplement (100 μL). Complete F12-K
media (100 μL) was added, and cells were further incubated for 1 h.
Cells were imaged using the Olympus CX41 microscope described
above (Supporting Information). The procedure was repeated with
the optimized ﬁnal concentration of AFPIII-Alexa Fluor 488 (0.8 mg·
mL−1) and Pep-1 (0.5 mg·mL−1). Fluorescence quantiﬁcation was
achieved using ﬂow cytometry, and confocal images were obtained
following ﬁxation with 4% paraformaldehyde (15 min) and staining
with NucBlue Live Cell ReadyProbes. Cells untreated and treated
solely with AFPIII-Alexa Fluor 488 (0.8 mg·mL−1) or Pep-1 (0.5 mg·
mL−1) in PBS:water (1:1) were also analyzed to determine
nonspeciﬁc binding, Pep-1 ﬂuorescence, and cell autoﬂuorescence.
Cell Suspension Freezing. Suspension freezing of A549 cells was
conducted under ﬁve conditions: (1) in DMSO solutions (0−10 wt
%); (2) in solutions containing AFPIII (0.05 mg·mL−1) and DMSO
(0−10 wt %); (3) incubated with Pep-1 (0.5 mg·mL−1) and
subsequently frozen in DMSO solutions (0−10 wt %); (4) transfected
with AFPIII (0.8 mg·mL−1) using Pep-1 (0.5 mg·mL−1) and frozen in
DMSO solutions (0−10 wt %); (5) transfected with AFPIII (0.8 mg·
mL−1) using Pep-1 (0.5 mg·mL−1) and frozen in solutions containing
DMSO (0−10 wt %) and AFPIII (0.05 mg·mL−1). For conditions (1)
and (2), A549 cells were obtained from an adherent culture and
placed in cryogenic vials at a density of 400k cell·mL−1 (400k cells per
vial) in unsupplemented F12-K media. F12-K media supplemented
with 20% FBS and DMSO (0−20 wt %) (1) or both DMSO (0−20
wt %) and AFPIII (0.1 mg·mL−1) (2) was added to the cryogenic vial
at a 1:1 ratio to achieve the desired ﬁnal concentration and cell
density. For treatments (4) and (5), AFPIII transfection into A549
cells using Pep-1 was completed as described above with the
optimized concentrations. Cells were also incubated with Pep-1 (0.5
mg·mL−1) dissolved in PBS:H2O (1:1), following the same protocol
for transfection but without AFPIII, to determine extent of Pep-1
inﬂuence on cell recovery after freeze−thawing (3). Following
completion of each treatment, cell detachment was achieved using
trypsin and placed in cryogenic vials at a density of 400k cell·mL−1
(400k cells per vial) in unsupplemented F12-K media. F12-K media
supplemented with 20% FBS and either DMSO (0−20 wt %) (3 and
4) or DMSO (0−20 wt %) and AFPIII (0.1 mg·mL−1) (5) was
subsequently added to the cryogenic vial at a 1:1 ratio to achieve the
desired ﬁnal concentration and cell density. Cryogenic vials were
placed in a CoolCell LX freezing container and frozen as described
previously during the optimization of AFPIII concentration for vial
freezing. Viable cells were counted using a hemocytometer, following
treatment with 0.4% trypan blue solution, and reported relative to the
total number of cells initially frozen. At least 4 biological repeats were
conducted.
Cell Monolayer Freezing. Monolayer freezing of A549 cells was
conducted using four treatments: (1) in DMSO solutions (0−10 wt
%); (2) in DMSO solutions (0−10 wt %) following incubation in
AFPIII (0.8 mg·mL−1); (3) incubated with Pep-1 (0.5 mg·mL−1) and
subsequently frozen in DMSO solutions (0−10 wt %); and (4)
AFPIII (0.8 mg·mL−1) transfection using Pep-1 (0.5 mg·mL−1) and
cryopreserved in DMSO solutions (0−10 wt %). A549 cells were
plated in a 24-well plate at a density of 800k cell·mL−1 (400k cells per
well), to achieve a conﬂuent monolayer, and left to attach for 24 h in a
humidiﬁed atmosphere of 5% CO2 and 95% air at 37 °C. The
following solutions were prepared in PBS: H2O (1:1) and added (100
μL) to the corresponding treatments: (1) PBS:H2O solution alone;
(2) AFPIII (0.8 mg·mL−1); (3) Pep-1 (0.5 mg·mL−1); (4) AFPIII
(0.8 mg·mL−1) and Pep-1 (0.5 mg·mL−1) after leaving for 30 min to
complex. A549 cells were incubated in these solutions for 30 min in a
humidiﬁed environment and for a further 1 h after adding F12-K
media without an additional supplement (100 μL). Complete F12-K
media (100 μL) was added, and cells were further incubated for 1 h.
All solutions were removed and, for every condition, cells were
incubated with DMSO (0−10 wt %) for 10 min. After 10 min, DMSO
solutions were removed and the plate was placed inside a CoolCell
MP plate (BioCision), transferred to a −80 °C freezer, and frozen at a
rate of 1 °C·min−1. After 24 h at −80 °C, cells were rapidly thawed
using complete F12-K media (500 μL) and placed in a humidiﬁed
atmosphere of 5% CO2 and 95% air at 37 °C for 24 h. Viable cells
were counted using a hemocytometer, following treatment with 0.4%
trypan blue solution, and reported relative to the total number of cells
initially frozen. Three biological repeats were conducted.
■ RESULTS AND DISCUSSION
To evaluate the intracellular versus extracellular impact of
macromolecular cryoprotectants, a type III antifreeze protein
from ocean pout (AFPIII) was selected. The rationale for using
an antifreeze protein, as opposed to polymeric cryoprotectants,
was their high IRI activity (capable of inhibiting all ice growth
well below 0.1 mg·mL−1)23 and the ability to use established
methods (see below) to enable cellular delivery of proteins.
Recombinant AFPIII was expressed in Escherichia coli (E. coli)
and puriﬁed according to previously published methods
(Supporting Information).51 Site-directed mutagenesis of the
terminal Ala present within the AFPIII encoding plasmid was
used to produce a mutant cysteine variant of AFPIII (AFP-
Cys), enabling site-speciﬁc conjugation to Alexa Fluor 488
Maleimide (AFPIII-Alexa Fluor 488) for ﬂuorescence-based
quantiﬁcation and imaging (Supporting Information).
A549 (adenocarcinomic human alveolar basal epithelial)
cells were chosen as a model cell line for cryopreservation
studies. To assess the role of intra- versus extracellular AFPIII
during mammalian cell cryopreservation, translocation of
AFPIII into the cells was essential. The cell-penetrating
peptide Pep-1 was selected for this purpose, as it is known
to be a broadly applicable cell-uptake enhancing peptide via a
nonendocytic mechanism.52−56 Due to the extensive literature
available on Pep-1 mediated translocation of protein cargoes,
the mechanism of complexation with AFPIII was not studied
here. There is evidence to suggest that Pep-1 forms a complex
with protein cargos through hydrophobic and electrostatic
interactions and adopts a helical structure upon interaction
with the plasma membrane lipids, allowing insertion into the
lipid bilayer. The complex is then released into the cytoplasm
with partial “decaging” of the cargo. However, the exact
mechanism of complexation was irrelevant to the cryopre-
servation of mammalian cells and the overall aim of this study.
To determine the minimum concentration of AFPIII
required for cellular delivery, a range of AFPIII-Alexa Fluor
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488 concentrations (0.125−1 mg·mL−1) were incubated with a
ﬁxed concentration of Pep-1 (0.5 mg·mL−1) for 30 min, to
form protein/peptide cargos, and subsequently applied to
A549 monolayers (2.5 h). AFPIII-Alexa Fluor 488 uptake was
monitored using ﬂuorescence microscopy (Supporting In-
formation, Figure S1). Internalization of AFPIII was observed
at concentrations of 0.5 and 1 mg·mL−1, so an intermediate
concentration of 0.8 mg·mL−1 was selected for the intracellular
delivery of AFPIII using Pep-1 in all subsequent experiments,
with a 1:1.65 molar ratio of AFPIII to Pep-1. Higher Pep-1/
cargo ratios are often used (20:1 or 10:1); however, previous
reports suggest that such high concentrations can result in the
formation of aggregates that are poorly taken into the cell and
accumulate on the cell surface or endosomes.53,55 Therefore, to
minimize these issues, while still ensuring AFPIII internal-
ization, a 1:1.65 molar ratio was optimal. Further (quantita-
tive) uptake studies were also explored (below). With a
working range established, the cytotoxicity of AFPIII toward
A549 cells was evaluated to ensure that any cryopreservative
eﬀects, either positive or negative, were not skewed by intrinsic
cytotoxicity. A549 cells were incubated with AFPIII (0−0.8
mg·mL−1) for 24 h and cell viability was assessed using the
resazurin reduction assay to determine any changes to cell
metabolic activity. Over 88% cell viability was obtained, even at
the highest concentrations, demonstrating minimal eﬀect to
cellular metabolic activity (Figure 1) and an advantage over
cytotoxic CPAs.
To further demonstrate the extent of intracellular incorpo-
ration of AFPIII with Pep-1, confocal images were obtained
using the optimized molar ratio of AFPIII-Alexa Fluor 488 and
Pep-1 (1:1.65) shown in Figure 2A. The peptide/protein cargo
was allowed to complex for 30 min and then applied to
conﬂuent monolayers of A549 cells for 2.5 h, mimicking the
suspension and monolayer pretreatment conditions used later
in the freezing protocol. Confocal images clearly indicated
enhanced uptake (green channel) when both Pep-1 (0.5 mg·
mL−1) and AFPIII-Alexa Fluor 488 (0.8 mg·mL−1) were
present, compared to AFPIII-Alexa Fluor 488 alone, suggesting
that AFPIII internalization is minimal without the use of Pep-1.
These results further validate our use of AFPIII for
investigating intracellular versus extracellular impact of macro-
molecular cryoprotectants on mammalian cell cryopreserva-
tion. This was further corroborated using ﬂow cytometry
analysis, with Pep-1 leading to approximately 5 times more
uptake of AFPIII (Figure 2B). Confocal z-stack images
revealed ﬂuorescence localized throughout the cytoplasm,
which was essential when assessing the importance of intra-
versus extracellular AFPIII (Supporting Information, Figures
S2−S5). In addition, there were no visible changes to A549 cell
morphology or membrane integrity when transfecting AFPIII
with Pep-1.
Following optimization of intracellular AFPIII delivery,
determining the optimum concentration of extracellular AFPIII
(in solution) was essential to maximize post-thaw cell recovery.
A549 cells were cryopreserved in a suspension containing
DMSO (0−10 wt %) and AFPIII (0−0.8 mg·mL−1). Cells
were allowed to recover for 24 h post-thaw, before determining
cell recovery (Figure 3). [Note: the 24 h incubation period
post-thaw is vital to avoid false positive results associated with
short post-thaw times, where any additive can give the
impression of cryoprotection if apoptotic processes are not
allowed time to complete].57 Cell recovery was determined
using the trypan blue exclusion assay for cell viability and the
total number of viable cells were compared to an unfrozen
control. This method provides total cell recovery, as damaged
cells are not counted, compared to methods that only measure
the viability of the recovered cells, which typically ignores
highly damaged cells and can overestimate cell recovery values
by not taking into account the number of cells recovered post-
thaw (e.g., 50% of cells recovered, however 100% are viable).
A549 cells were also frozen in equivalent DMSO solutions (0−
10 wt %) to provide a comparable standard freezing approach
for the assessment of post-thaw cell recovery. Unsurprisingly,
A549 cells frozen in 10 wt % DMSO alone outperformed lower
concentrations for this cell line, with an average post-thaw
recovery of 67%. These results are consistent with those
reported by Bailey et al.48 Addition of AFPIII at 0.8 mg·mL−1
to the media resulted in a dramatic loss in post-thaw cells at all
DMSO concentrations. The decrease in cell viability witnessed
Figure 1. AFPIII cytotoxicity against A549 cells. Cells were incubated
with AFPIII (0−0.8 mg·mL−1 for 24 h) and cellular metabolic activity
was assessed using the resazurin reduction assay. The data is
represented by the mean value ± SEM (n = 3, n.s. p > 0.05, *p ≤ 0.05
compared to cells untreated with AFPIII).
Figure 2. AFPIII translocation into A549 cells using Pep-1. (A)
Confocal microscopy (merge blue and green channels) and (B) ﬂow
cytometry analysis of AFPIII-AlexaFluor488 (0.8 mg·mL−1) delivery
using Pep-1 (0.5 mg·mL−1). Scale bar = 20 μm. Blue = DAPI. Green =
AFPIII-Alexa Fluor 488.
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at high AFPIII concentrations is consistent with previous work,
where AFPIII’s ice shaping capabilities result in the formation
of destructive “needle-shaped” ice which can pierce cell
membranes and vital internal structures during freez-
ing.20,33,58,59 Lower concentrations of AFPIII (0.1 and 0.05
mg·mL−1) lead to almost identical results to DMSO alone,
with slight diﬀerences in cell recovery being statistically
insigniﬁcant. During freezing, AFPIII adsorbs onto prismatic
and bipyramidal ice faces without attaching to basal faces,
allowing the development of bipyramidal ice crystals, which
“burst” along the c-axis when the freezing point is reached
forming “needle-shaped” ice crystals. Vorontsov et al.60 and
Ishiguro and Rubinsky61 revealed that lower AFPIII concen-
trations form dendritic ice growth whereas higher concen-
trations result in the development of cell damaging spicular ice
crystals. Thus, to avoid cell injury and maximize recoveries
post-thaw, 0.05 mg·mL−1 AFPIII was used as the external CPA
concentration for further suspension cryopreservation studies.
As a ﬁnal control, it was also necessary to conﬁrm if the
presence of Pep-1 had any impact on the ice recrystallization
inhibition (IRI) activity of AFPIII, a crucial cryoprotective
function of this protein, as any changes could give rise to false
positive cryopreservation results. The “splat” assay was used to
assess changes in IRI activity, whereby small ice crystals are
nucleated in a wafer and annealed at −8 °C for 30 min.62,63
Following this, the mean grain size of the crystals was
determined, and reported relative to a negative control (PBS).
AFPIII demonstrated potent IRI activity, as shown in Figure 4,
inhibiting all ice growth at concentrations below 0.01 mg·
mL−1. This value is consistent with previous reports,
demonstrating superior and consistent IRI capabilities
compared to other cryopreservants.51 This recrystallization
inhibition eﬀect is maintained, if not slightly enhanced, in the
presence of 0.5 mg·mL−1 Pep-1, which is the working
concentration of the peptide used in this study. Pep-1 alone
was found to present negligible IRI activity, eliminating the
possibility of results being enhanced or depleted by Pep-1
interactions. These results indicate that Pep-1 translocation of
AFPIII was an ideal choice to ensure AFPIII’s IRI activity was
retained, allowing a direct comparison between the beneﬁts of
localizing IRI active macromolecules intra- versus extracellu-
larly.
Guided by the above data, the impact of intra/extracellular
AFPIII on cryopreservation was evaluated. A549 cells were
cryopreserved in suspension using 0−10 wt % DMSO alone, or
with AFPIII either complexed with Pep-1 or AFPIII alone. Cell
recovery was determined 24 h post-thaw using the trypan blue
exclusion assay. As can be seen in Figure 5, Pep-1 alone lead to
a small decrease in post-thaw recovery in 10 wt % DMSO. A
resazurin reduction assay was completed of Pep-1, Figure S7,
revealing that uncomplexed Pep-1 at the concentrations used
to complex with AFPIII, results in a signiﬁcant (P ≤ 0.05)
decrease in cell viability. Therefore, this slight decrease in cell
recovery can be attributed to uncomplexed Pep-1 cytotoxicity.
The presence of AFPIII intracellularly, extracellularly, or both,
surprisingly lead to minimal changes in post-thaw cell recovery.
A small decrease in cell recovery was noted in the presence of
intracellular AFPIII at all DMSO concentrations, but this was
found to be statistically insigniﬁcant. There have been previous
reports of intracellular ice recrystallization inhibitors enhancing
the cryopreservation of red blood cells using glycerol (red
blood cells are not stored in DMSO);32 however, in that
particular case, the conditions (low glycerol and transient
cooling/warming) were deliberately chosen to promote
intracellular ice growth. Here, by using slow freezing rates
lethal intracellular ice growth should be prevented/reduced
however the formation of extracellular ice growth remains an
issue. Extracellular AFPIII only increased post-thaw cell
viability by approximately 6% at equal DMSO concentrations
between 2 and 10 wt %. This data supports the hypothesis that,
for optimized suspension cryopreservation systems (such as
this one), inhibiting ice recrystallization does not signiﬁcantly
increase viability. The highest percentage increase occurred
Figure 3. Post-thaw cell viability following suspension freezing of
A549 cells with AFPIII. A549 cells were cryopreserved in DMSO (0−
10 wt %) and AFP (0−0.8 mg·mL−1) for 24 h at −80 °C. Recovered
cells were counted by trypan blue exclusion assay relative to unfrozen
controls. The data represents the mean value ± SEM (n = 4, n.s. p >
0.05, ***p ≤ 0.001 compared to cell recovery at equivalent DMSO
concentrations with no AFPIII).
Figure 4. Ice recrystallization inhibition of AFPIII with or without
Pep-1. (A) Example cryo-micrographs of ice wafers after 30 min of
annealing with AFPIII in the presence and absence of Pep-1 (0.5 mg·
mL−1). (B) Dose-dependence of ice recrystallization inhibition
activity. Mean grain size was calculated relative to PBS (negative)
control. The data represents the mean value ± SEM (n = 3).
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when 2 wt % DMSO was used, with an increase from 13.1% to
21.0%, a nonideal concentration for these cells. Unfortunately,
percentage recovery values still remained low despite the
presence of AFPIII as the lack of DMSO most likely
introduced additional mechanisms of cell death which IRI
active compounds do not account for including exposure to
excessively high concentrations of electrolytes (“solute eﬀect”)
causing irreparable damage to the cell membrane and osmotic
volume excursions exceeding cell tolerance.4 However,
extracellular AFPIII (or other IRIs) appeared to show
application in the cryopreservation of cells requiring low
DMSO storage, due to susceptibility to cytotoxicity or induced
diﬀerentiation, and where ice recrystallization is a more
signiﬁcant contributor to cell death.
The above results suggested that the intra/extracellular
localization of AFPIII was not suﬃcient for enhancing
mammalian cell cryopreservation in suspension freezing.
While this is the most standard cell cryopreservation format,
there is a real need to develop technologies and methods for 2-
and 3-D cell models, for tissue storage and organ-on-a-chip
applications.13−15 The monolayer freezing protocol is illus-
trated in Figure 6A. A549 monolayers were frozen in DMSO
alone, or with AFPIII (0.8 mg·mL−1), AFPIII (0.8 mg·mL−1)
plus Pep-1 (0.5 mg·mL−1)), or Pep-1 alone (0.5 mg·mL−1).
Cells were incubated with these cryoprotectants for 2.5 h,
except for DMSO alone where incubation with media was
completed, followed by incubation with DMSO (0−10 wt %)
concentrations for 10 min. This procedure allowed time for
intracellular translocation of Pep-1 with AFPIII and main-
tained the same AFPIII, Pep-1, and DMSO exposure times
under all relevant conditions. Excess solution was removed,
and cell monolayers were frozen at a controlled freezing rate of
1 °C·min−1 to −80 °C using a CoolCell MP plate. Confocal
images revealed that incubation with DMSO did not aﬀect the
cells’ ability to retain transfected AFPIII (Supporting
Information, Figures S2−S5).
As expected, cryopreservation in DMSO alone lead to
limited cell recovery, with 25% cell recovery achieved using 10
wt % DMSO, substantially lower compared to suspension cell
cryopreservation due to the intercellular contacts and limited
diﬀusion between cells, minimizing DMSO’s capabilities of
reducing intracellular ice growth. Lower DMSO concentrations
provided less recovery. Surprisingly, Pep-1 alone resulted in a
signiﬁcant decrease in cell recovery. As previously discussed,
uncomplexed Pep-1 is cytotoxic at the concentrations used;
however, resazurin reduction was still 80% relative to control
cells, Figure S7. Thus, cytotoxicity cannot be the only
contributing factor. Uncomplexed Pep-1 may be interacting
with membrane proteins and thus weakening membrane
integrity and making it more susceptible to ice damage.
Intracellular AFPIII lead to an increase in cell recovery at all
DMSO concentrations, however with high variability.
Compared to all other treatments, intracellular AFPIII
provided the highest increase in cell recoveries, from 0.3% to
10.5%, when 2 wt % DMSO (i.e., lower DMSO concen-
trations) was used. Poisson et al.64 demonstrated that cell
permeable small molecules, aryl glycosides, possessing IRI
activity can reduce intracellular ice recrystallization content
and increase post-thaw cell viability of red blood cells and
human umbilical vein endothelial cells frozen with low
glycerol. DMSO and glycerol both provide cryoprotection
using the same mechanism of action, by reducing the
Figure 5. Suspension cryopreservation of A549 cells. (A) Cells were
frozen with internalized AFPIII (0.8 mg·mL−1) translocated using
Pep-1 (0.5 mg·mL−1) (AFPin), AFPIII within the CPA (0.05 mg·
mL−1) (AFPout) or both (AFPin/out) and with varying DMSO
concentrations (0−10 wt %). Control cells were also cryopreserved
in DMSO and Pep-1 for comparison. (B) Post-thaw cell recovery was
calculated by trypan blue exclusion assay relative to unfrozen controls.
The data represents the mean value ± SEM (n ≥ 4, n.s. p > 0.05
compared to cell recovery at equivalent DMSO concentrations with
no AFPIII).
Figure 6. A549 cell monolayer cryopreservation. (A) Cells were
incubated with either media (DMSO), Pep-1 (0.5 mg·mL−1), AFPIII
(0.8 mg·mL−1) translocated using Pep-1 (0.5 mg·mL−1) (AFPin) or
AFPIII within the solution (0.8 mg·mL−1) (AFPout) for 2.5 h.
Following removal of solutions, cells were incubated with DMSO
concentrations (0−10 wt %) and frozen at 1 °C·min−1 to −80 °C. (B)
Cell recovery was determined by trypan blue exclusion assay relative
to unfrozen controls. The data represents the mean value ± SEM (n =
3; n.s. p > 0.05, *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 compared to
percentage cell recovery values at equivalent DMSO concentrations
with no AFPIII).
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concentration of either CPAs the risk of intracellular ice
growth increases. This suggests that intracellular AFPIII is
likely reducing intracellular ice recrystallization, thus reducing
the chances of larger crystals forming during freeze−thaw and
cell death. Intracellular ice is particularly problematic in
monolayer freezing due to intracellular ice propagation from
cell−cell and cell−surface interaction with adjacent cells, or
gap junctions within the membrane.41,43,44 Therefore, intra-
cellular localization of IRI active compounds, such as AFPIII,
may ﬁnd use in situations where lower DMSO concentrations
are beneﬁcial.
Extracellular AFPIII gave rise to signiﬁcant increases in post-
thaw recovery for all DMSO concentrations, especially at
higher DMSO concentration (5−10 wt %). In fact, 10 wt %
DMSO increased the recovery rate from 25% to 60% upon
addition of AFPIII. Extracellular AFPIII combined with 5 wt %
DMSO also demonstrated a large increase in cell recovery (1.6-
fold), compared to the equivalent DMSO alone cell recoveries,
and demonstrated the highest statistically signiﬁcant increase
compared to all other combination of treatments. In addition,
extracellular AFPIII at 5 wt % DMSO also obtained cell
recoveries (38%) greater than 10 wt % DMSO alone,
demonstrating that external AFPIII (in solution) could be
used to reduce the total DMSO concentration required (which
is biomedically important) while enhancing post-thaw cell
recovery. Acker et al. demonstrated that, although intracellular
ice formation is regarded as an inherently lethal event,
innocuous intracellular ice exists and may even increase post-
thaw cell viability of multiple cell lines using slow freezing.65,66
Therefore, it is possible that extracellular ice growth
recrystallization is the dominant cause of cell death and IRI
active compounds are hence more potent when extracellular.
Alternatively, nonspeciﬁc uptake of AFPIII could inhibit
intracellular ice recrystallization suﬃciently to avoid crystal
sizes which have been deemed harmful in previous studies.67
AFPs are known to stabilize fatty acids located throughout the
membrane during freezing and can cause membrane leakage,
however this is highly dependent on lipid composition of the
bilayer and thus individual cell types.68−70 Membrane leakage
would allow the eﬄux of water, and most likely exchange with
DMSO, to occur rapidly and prevent extensive intracellular ice
growth. Regardless of the exact mechanism, these results
conﬁrm that, at least when DMSO is used on cell monolayers,
that extracellular localization of antifreeze proteins provide
signiﬁcant beneﬁt to monolayer cryopreservation of cells
which, according to previous literature, is likely correlated to
their ice recrystallization inhibition activity or membrane
interactions. These eﬀects were clearly less important for
suspension cell cryopreservation suggesting that the primary
mechanism of cell death are diﬀerent in the two systems, and
the cryoprotectants required will vary depending on the
complexity of the cellular system being cryopreserved.
■ CONCLUSIONS
Here we present a study into the role of intra- versus
extracellular antifreeze proteins, on the cryopreservation of a
model cell line, showing how this localization has a dramatic
eﬀect on post-thaw cell recovery. The Pep-1 cell-penetrating
peptide was employed to deliver recombinantly expressed type
III antifreeze protein into A549 cells. Intracellular delivery was
conﬁrmed using confocal microscopy and ﬂow cytometry,
showing 5 times more internalization of AFPIII. Using
conventional suspension cell freezing methods, with DMSO
as the cryoprotectant, the antifreeze protein demonstrated
minimal impact on post-thaw cell recovery, whether it was
intra- or extracellular. This suggests that the primary mode of
cell death in this system was not due to unwanted ice
recrystallization, and hence the antifreeze protein oﬀered
limited protection. The same delivery strategy was sub-
sequently applied to 2-D cell monolayers, a more challenging
cell cryopreservation system where DMSO alone fails to enable
signiﬁcant cell recovery. Without the antifreeze protein, only
∼25% of monolayer-frozen cells were recovered post-thaw.
Insigniﬁcant increases in post-thaw recovery was observed
when the antifreeze protein was delivered into the cell;
however, when applied extracellularly, the post-thaw recovery
of cells rose from 25% to over 60%, representing a remarkable
increase. These results provide evidence that extracellular
macromolecular cryoprotectants result in superior cryoprotec-
tive eﬀects when supplemented to DMSO cryopreservation
and provides evidence that antifreeze proteins, and potentially
additional macromolecular cryoprotectants, do not need to be
designed with cellular uptake as a criterion. This work also
shows that the requirements to enhance cell monolayer
recovery are distinct from suspension, so a “one size ﬁts all”
approach might not always be suitable. Finally, these results
show that the mechanisms of cell death during cryopreserva-
tion vary between systems. In summary, this work provides
new insight into the requirements of a macromolecular
cryoprotectant and provides a step forward toward being
able to rationally design new materials to enable new therapies
and biotechnological tools.
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